| Symbol | IDYA |
|---|---|
| Name | IDEAYA BIOSCIENCES, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 5000 SHORELINE COURT,SUITE 300, SOUTH SAN FRANCISCO, California, 94080, United States |
| Telephone | +1 650 - 443-6209 |
| Fax | — |
| — | |
| Website | https://www.ideayabio.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001676725 |
| Description | IDEAYA Biosciences Inc an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. The companys product candidate IDE196 is a protein kinase C, or PKC, an inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations. Additional info from NASDAQ: |
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Read moreIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Read moreIDEAYA Biosciences Announces Yujiro S. Hata Elected Chairman of its Board of Directors
Read moreIDEAYA Biosciences Announces Yujiro S. Hata Elected Chairman of its Board of Directors
Read moreIDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers
Read moreIDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers
Read more(99% Neutral) IDEAYA BIOSCIENCES, INC. (IDYA) Announces Business Combination
Read moreIDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters Option to Purchase Additional Shares
Read moreIDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters Option to Purchase Additional Shares
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07540572 | A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy o… | Phase1 | ER+, HER 2- Breast Cancer | Recruiting | 2026-03-17 | 2030-06-30 | ClinicalTrials.gov |
| NCT07277413 | A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid… | Phase1 | NSCLC Adenocarcinoma | Recruiting | 2026-03-04 | 2028-04-30 | ClinicalTrials.gov |
| NCT07503808 | A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid … | Phase1 | Esophageal Squamous Cell Carcinoma | Recruiting | 2026-02-24 | 2027-07-30 | ClinicalTrials.gov |
| NCT07015190 | Neoadjuvant Darovasertib in Primary Uveal Melanoma | Phase3 | Uveal Melanoma | Recruiting | 2026-01-25 | 2031-03-01 | ClinicalTrials.gov |
| NCT07174583 | A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell … | Phase1 | Small-cell Lung Cancer | Recruiting | 2025-10-14 | 2029-05-01 | ClinicalTrials.gov |
| NCT06710847 | A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiven… | Phase1 | Neoplasms, Colorectal | Active_Not_Recruiting | 2024-12-13 | 2026-06-22 | ClinicalTrials.gov |
| NCT05987332 | IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in M… | Phase2 | Metastatic Uveal Melanoma | Active_Not_Recruiting | 2023-10-31 | 2028-01-15 | ClinicalTrials.gov |
| NCT05907954 | (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma | Phase2 | Uveal Melanoma | Active_Not_Recruiting | 2023-07-03 | 2030-04-30 | ClinicalTrials.gov |
| NCT04794699 | Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion | Phase1 | Solid Tumor | Active_Not_Recruiting | 2021-04-14 | 2027-02-04 | ClinicalTrials.gov |
| NCT03947385 | Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PR… | Phase1 | Metastatic Uveal Melanoma | Recruiting | 2019-06-28 | 2027-06-15 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| IDE397 | Other | Phase PHASE1 | NSCLC Adenocarcinoma | RECRUITING | NCT07277413 |
| IDE892 | Other | Phase PHASE1 | NSCLC Adenocarcinoma | RECRUITING | NCT07277413 |
| IDE034 | Other | Phase PHASE1 | Esophageal Squamous Cell Carcinoma | RECRUITING | NCT07503808 |
| Fulvestrant injection | Other | Phase PHASE1 | ER+, HER 2- Breast Cancer | RECRUITING | NCT07540572 |
| IDE574 | Other | Phase PHASE1 | ER+, HER 2- Breast Cancer | RECRUITING | NCT07540572 |
| IDE397 | Other | Phase PHASE1 | NSCLC Adenocarcinoma | RECRUITING | NCT07277413 |
| IDE892 | Other | Phase PHASE1 | NSCLC Adenocarcinoma | RECRUITING | NCT07277413 |
| Crizotinib | Other | Phase PHASE1 | Metastatic Uveal Melanoma | RECRUITING | NCT03947385 |
| Binimetinib | Other | Phase PHASE1 | Metastatic Uveal Melanoma | RECRUITING | NCT03947385 |
| IDE196 | Other | Phase PHASE1 | Metastatic Uveal Melanoma | RECRUITING | NCT03947385 |
| Fulvestrant injection | Other | Phase PHASE1 | ER+, HER 2- Breast Cancer | RECRUITING | NCT07540572 |
| IDE574 | Other | Phase PHASE1 | ER+, HER 2- Breast Cancer | RECRUITING | NCT07540572 |
| Fulvestrant injection | Other | Phase PHASE1 | ER+, HER 2- Breast Cancer | RECRUITING | NCT07540572 |
| IDE574 | Other | Phase PHASE1 | ER+, HER 2- Breast Cancer | RECRUITING | NCT07540572 |
| Fulvestrant injection | Other | Phase PHASE1 | ER+, HER 2- Breast Cancer | RECRUITING | NCT07540572 |
| IDE574 | Other | Phase PHASE1 | ER+, HER 2- Breast Cancer | RECRUITING | NCT07540572 |
| Fulvestrant injection | Other | Phase PHASE1 | ER+, HER 2- Breast Cancer | RECRUITING | NCT07540572 |
| IDE574 | Other | Phase PHASE1 | ER+, HER 2- Breast Cancer | RECRUITING | NCT07540572 |
| Fulvestrant injection | Other | Phase PHASE1 | ER+, HER 2- Breast Cancer | RECRUITING | NCT07540572 |
| IDE574 | Other | Phase PHASE1 | ER+, HER 2- Breast Cancer | RECRUITING | NCT07540572 |
| Fulvestrant injection | Other | Phase PHASE1 | ER+, HER 2- Breast Cancer | RECRUITING | NCT07540572 |
| IDE574 | Other | Phase PHASE1 | ER+, HER 2- Breast Cancer | RECRUITING | NCT07540572 |
| Fulvestrant injection | Other | Phase PHASE1 | ER+, HER 2- Breast Cancer | RECRUITING | NCT07540572 |
| IDE574 | Other | Phase PHASE1 | ER+, HER 2- Breast Cancer | RECRUITING | NCT07540572 |
| Fulvestrant injection | Other | Phase PHASE1 | ER+, HER 2- Breast Cancer | RECRUITING | NCT07540572 |
| IDE574 | Other | Phase PHASE1 | ER+, HER 2- Breast Cancer | RECRUITING | NCT07540572 |
| Fulvestrant injection | Other | Phase PHASE1 | ER+, HER 2- Breast Cancer | RECRUITING | NCT07540572 |
| IDE574 | Other | Phase PHASE1 | ER+, HER 2- Breast Cancer | RECRUITING | NCT07540572 |
| Fulvestrant injection | Other | Phase PHASE1 | ER+, HER 2- Breast Cancer | RECRUITING | NCT07540572 |
| IDE574 | Other | Phase PHASE1 | ER+, HER 2- Breast Cancer | RECRUITING | NCT07540572 |
| Fulvestrant injection | Other | Phase PHASE1 | ER+, HER 2- Breast Cancer | RECRUITING | NCT07540572 |
| IDE574 | Other | Phase PHASE1 | ER+, HER 2- Breast Cancer | RECRUITING | NCT07540572 |
| Fulvestrant injection | Other | Phase PHASE1 | ER+, HER 2- Breast Cancer | RECRUITING | NCT07540572 |
| IDE574 | Other | Phase PHASE1 | ER+, HER 2- Breast Cancer | RECRUITING | NCT07540572 |
| Primary Local Therapy | Drug | Phase PHASE3 | Uveal Melanoma | RECRUITING | NCT07015190 |
| Darovasertib | Other | Phase PHASE3 | Uveal Melanoma | RECRUITING | NCT07015190 |
| Primary Local Therapy | Drug | Phase PHASE3 | Uveal Melanoma | RECRUITING | NCT07015190 |
| Darovasertib | Other | Phase PHASE3 | Uveal Melanoma | RECRUITING | NCT07015190 |
| Primary Local Therapy | Drug | Phase PHASE3 | Uveal Melanoma | RECRUITING | NCT07015190 |
| Darovasertib | Other | Phase PHASE3 | Uveal Melanoma | RECRUITING | NCT07015190 |
| Primary Local Therapy | Drug | Phase PHASE3 | Uveal Melanoma | RECRUITING | NCT07015190 |
| Darovasertib | Other | Phase PHASE3 | Uveal Melanoma | RECRUITING | NCT07015190 |
| Primary Local Therapy | Drug | Phase PHASE3 | Uveal Melanoma | RECRUITING | NCT07015190 |
| Darovasertib | Other | Phase PHASE3 | Uveal Melanoma | RECRUITING | NCT07015190 |
| Primary Local Therapy | Drug | Phase PHASE3 | Uveal Melanoma | RECRUITING | NCT07015190 |
| Darovasertib | Other | Phase PHASE3 | Uveal Melanoma | RECRUITING | NCT07015190 |
| Primary Local Therapy | Drug | Phase PHASE3 | Uveal Melanoma | RECRUITING | NCT07015190 |
| Darovasertib | Other | Phase PHASE3 | Uveal Melanoma | RECRUITING | NCT07015190 |
| Primary Local Therapy | Drug | Phase PHASE3 | Uveal Melanoma | RECRUITING | NCT07015190 |
| Darovasertib | Other | Phase PHASE3 | Uveal Melanoma | RECRUITING | NCT07015190 |
| IDE397 | Other | Phase PHASE1 | NSCLC Adenocarcinoma | RECRUITING | NCT07277413 |
| IDE892 | Other | Phase PHASE1 | NSCLC Adenocarcinoma | RECRUITING | NCT07277413 |
| IDE161 | Other | Phase PHASE1 | Small-cell Lung Cancer | RECRUITING | NCT07174583 |
| durvalumab | Other | Phase PHASE1 | Small-cell Lung Cancer | RECRUITING | NCT07174583 |
| IDE849 | Other | Phase PHASE1 | Small-cell Lung Cancer | RECRUITING | NCT07174583 |
| Crizotinib | Other | Phase PHASE1 | Metastatic Uveal Melanoma | RECRUITING | NCT03947385 |
| Binimetinib | Other | Phase PHASE1 | Metastatic Uveal Melanoma | RECRUITING | NCT03947385 |
| IDE196 | Other | Phase PHASE1 | Metastatic Uveal Melanoma | RECRUITING | NCT03947385 |
| PD-1 inhibitor | Other | Phase PHASE1 | Neoplasms, Colorectal | ACTIVE_NOT_RECRUITING | NCT06710847 |
| GSK4418959 | Other | Phase PHASE1 | Neoplasms, Colorectal | ACTIVE_NOT_RECRUITING | NCT06710847 |
| Pembrolizumab | Other | Phase PHASE1 | Advanced or Metastatic Solid Tumors | RECRUITING | NCT05787587 |
| IDE-161 | Other | Phase PHASE1 | Advanced or Metastatic Solid Tumors | RECRUITING | NCT05787587 |
| Dacarbazine | Other | Phase PHASE2 | Metastatic Uveal Melanoma | ACTIVE_NOT_RECRUITING | NCT05987332 |
| Nivolumab | Other | Phase PHASE2 | Metastatic Uveal Melanoma | ACTIVE_NOT_RECRUITING | NCT05987332 |
| Ipilimumab | Other | Phase PHASE2 | Metastatic Uveal Melanoma | ACTIVE_NOT_RECRUITING | NCT05987332 |
| Pembrolizumab | Other | Phase PHASE2 | Metastatic Uveal Melanoma | ACTIVE_NOT_RECRUITING | NCT05987332 |
| Crizotinib | Other | Phase PHASE2 | Metastatic Uveal Melanoma | ACTIVE_NOT_RECRUITING | NCT05987332 |
| IDE196 | Other | Phase PHASE2 | Metastatic Uveal Melanoma | ACTIVE_NOT_RECRUITING | NCT05987332 |
| Primary Local Therapy | Drug | Phase PHASE3 | Uveal Melanoma | RECRUITING | NCT07015190 |
| Darovasertib | Other | Phase PHASE3 | Uveal Melanoma | RECRUITING | NCT07015190 |
| Darovasertib | Other | Phase PHASE2 | Uveal Melanoma | ACTIVE_NOT_RECRUITING | NCT05907954 |
| IDE034 | Other | Phase PHASE1 | Esophageal Squamous Cell Carcinoma | RECRUITING | NCT07503808 |
| Sacituzumab govitecan | Other | Phase PHASE1 | Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04794699 |
| IDE397 | Other | Phase PHASE1 | Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04794699 |
| Fulvestrant injection | Other | Phase PHASE1 | ER+, HER 2- Breast Cancer | RECRUITING | NCT07540572 |
| IDE574 | Other | Phase PHASE1 | ER+, HER 2- Breast Cancer | RECRUITING | NCT07540572 |